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Abstract  
The aim of this study is to define a new statistic, PVL, based on the relative 
distance between the likelihood associated with the simulation replications and the 
likelihood of the conceptual model. Our results coming from several simulation 
experiments of a clinical trial show that the PVL statistic range can be a good measure 
of stability to establish when a computational model verifies the underlying conceptual 
model. PVL  improves also the analysis of simulation replications because only one 
statistic is associated with all the simulation replications. As well it  presents several 
verification scenarios, obtained by altering the simulation model, that show the 
usefulness of PVL. Further simulation experiments suggest that a 0 to 20 % range may 
define adequate limits for the verification problem, if considered from the viewpoint of 
an equivalence test. 
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1. Introduction 
A very important problem in simulation is the reliability of the conceptual and 
computational models, that is, the validation and verification problem (See for example 
Sargent (2003) and Nance and Sargent (2002) for an exhaustive summary). The 
conceptual model is defined as a mathematical model that expresses reality and the 
computational model (simulation model) as the implementation of a conceptual model 
via an algorithm or software. 
Holford et al (2000)  indicates that clinical trial simulation is mainly performed 
for two purposes: to extrapolate experimental results to different conditions from those 
used to build the conceptual model (time, doses, etc.) and to optimize, considering 
alternative designs, sample sizes, sampling schemes, etc. The importance of simulation 
in the field of clinical trials gave rise to a best practices document (Holford, 1999) 
offering directives, which are accurate enough, but neither specify how to perform the 
simulations nor how to analyze the results. 
The most common experimental designs in this field are repeated measurements 
and one of the best ways to model them is using mixed models (see e.g. Hand et al, 
1987). These allow the fixed and the random parts to be built in separately from the 
effects of the experimental factors, such as time, pharmacological treatment, and 
covariates such as sex, weight, complementary physiological measures, etc. 
Mixed models successfully model correlations between measurements from the 
same individual at different times (repeated measurements) using a suitable covariance 
structure. Appendices A and B outline the introductory theory of mixed models, Monte 
Carlo simulation, and the calculation of the number of simulation replications. 
One of the most important problems in clinical trial simulations is how to 
measure the stability of the simulations (in the sense of the degree to which simulation 
software can be run without crashing, errors in the coding of the conceptual model or 
otherwise malfunctioning). From a statistical point of view, validation and verification 
are goodness of fit (GOF) problems. In this context, the use of statistical hypotheses has 
many methodological disadvantages, especially for determining the range giving an 
acceptable precision in the verification of the model. The simulation model is obtained 
by implementing the model on the specified computer system, which includes 
programming the conceptual model whose specifications are contained in the simulation 
model specification. Inferences about the system are obtained by conducting computer 
experiments (experimenting) on the simulation model (Sargent, 2003). 
 3
The process of validation concerns how the conceptual model fits reality and is 
usually defined to mean “substantiation that a computerized model within its domain of 
applicability possesses a satisfactory range of accuracy consistent with the intended 
application of the model” (Schlesinger et al, 1979) . A model should be developed for a 
specific purpose (or application) and its validity determined with respect to that 
purpose. If the purpose of a model is to answer a variety of questions, the validity of the 
model needs to be determined with respect to each question. Operational validation 
checks that the data generated by the computational model have statistical properties 
comparable to those of real data. During verification is checked  whether the behaviour 
of the computational model adequately implements the conceptual model, that has been 
judged adequated before for the purpose or its utility.  
Model verification is often defined as “ensuring that the computer programming 
and implementation of the conceptual model are correct” and is the definition is 
internationally accepted (Sargent, 2003; Balci, 1998) and adopted here. The most recent 
tendencies in simulation (Thacker et al, 2005)  concludes that verification is concerned 
with identifying and removing errors in the model by comparing numerical solutions to 
analytical or highly accurate benchmark solutions. Validation, on the other hand, is 
concerned with quantifying the accuracy of the model by comparing numerical 
solutions to experimental data. In short, verification deals with the mathematics 
associated with the model, whereas validation deals with the physics associated with the 
model (Roach, 1998). Because mathematical errors can cancel out, giving the 
impression of correctness (right answer for the wrong reason), verification should be 
performed before the validation activity begins . 
Sargent (2003) and Nance et al (2002) described four different approaches to 
deciding model validity; two different paradigms that relate verification and validation 
to the model development process and various methods of model verification 
techniques, also an extensive described of validation and verification techniques were 
wide described in Monleón (2005). Otherwise Balci (1998) and Whiner et al. (1998) 
present guidelines for conducting verification, validation, and accreditation (VV&A) of 
model and simulation (M&S) applications. In the real world of modelling there is a 
process of model building that involves trying different conceptual models. The best of 
these models e.g. based on a likelihood ratio test (LRT), is then chosen as the final 
model to describe the data. 
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The aim of this study is to define a new statistic, PVL, based on a GOF criterion, 
to measure the stability of a simulation or computational model compared to its 
underlying conceptual model. It is based on the relative difference between the 
likelihood associated with the simulation replications and the likelihood of the 
conceptual model. Its use as a verification measure will be illustrated by means of a real 
clinical trial simulation where the conceptual model is a linear mixed model. 
 
2. A measure of stability for verifying simulation models 
To verify computational models compared to the underlying conceptual models 
using a set of simulation replication results, confidence intervals for the fixed part and 
variances and covariances for the random part parameters of the conceptual model are 
currently used (Sargent, 2003); Monleón, 2005; Monleón and Ocaña, 2006; Rodríguez-
Barrios et al, 2008). Additionally the errors and the statistical significances (p-values) 
for the main factors (treatment, time, and interaction time × treatments in a typical 
clinical trial) can also be used. This method has the inconvenience of being extremely 
demanding in time and it was rejected as a general approach. Most of the techniques 
described in the literature has been used for validating and verifying the submodels and 
overall model, and can be used either subjectively or objectively. By “objectively”we 
mean using some type of statistical test or mathematical procedure, e.g., hypothesis tests 
or confidence intervals. A combination of techniques is generally used (Sargent, 2003) 
during V&V process.  
Parameters and p-values can show whether the computational model is 
reasonably comparable to the conceptual model, but the use of statistical hypotheses has 
many methodological disadvantages. They do not allow us to quantitatively establish 
the difference that exists between conceptual and computational models. This includes 
the totality of the simulation replications and obtaining a measurement of its stability 
when faced with different model disturbances, such as the supposition of new scenarios 
(variability and design), mistakes during the transcription of the conceptual model in 
algorithm form, or bugs in the random generation algorithm during simulation. We need 
a measure to determine the range of the acceptable precision in the computational model 
verification for its future re-use when the modeller needs to extend the use of the 
computational model to a new experimental situation. 
         To solve this problem from a statistical point of view, and considering validation 
and verification as a GOF problem, we propose the use of a new statistic as a measure 
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of stability of the simulation model based on a simulated Log–Likelihood GOF criterion 
(LLK) calculated as -2 Res log L, where Res log L is the logarithm of the maximum 
restricted likelihood function (Monleón and Ocaña, 2006); Monleón et al, 2004). This 
index may be computed in conjunction with other likelihood criteria such as AIC, AICC 
(Small variation of AIC) and BIC, and calculated in every simulation replication.  
The likelihood variation percentage compared to the conceptual model 
likelihood (PVL, Percentage variation of likelihood) for every simulation replication 
(Figure 3) may be defined as: 
⎛ ⎞ −= ⎜ ⎟⎝ ⎠
100 a b ii
b b
n LLR LLRPVL
n LLR
                                                    (1) 
where LLRb is the LLK calculated in the conceptual model, LLRi is the value of LLK 
obtained in simulation replication i=1 to R, na is the number of cases computed in the 
conceptual model, nb is the number of cases simulated in the computational model (nb = 
na when the sample size and design of the original experiment is used for the 
simulation). PVLi is calculated using a GOF based on LLK criteria. AIC, AICC and BIC 
were calculated in the same way. PVLi is a positive definite distance. 
The stability distance between the computational and conceptual models is 
defined as the PVL range (ul-ll) and composed of the PVL upper limit (ul) = 
= 1( ,..., )ul RPVL Max PVL PVL  and the PVL lower limit (ll) 
= = 1( ,..., )ll RPVL Min PVL PVL . 
Another measure to verify simulation models could be the LLR intra-replications 
(PVLIR) calculated as, 
−= 2
2
100 ii
LLR LLRPVLIR
LLR
                                               (2) 
 
Where LLR2 is the 1( ,..., )RMax LLR LLR  for all R estimated in the simulated model. 
LLRi corresponds to every value of LLR obtained in one of the 1,….,R replications. 
The next section develops a case study; modelling, simulation, and the results of 
verification using the proposed measure of stability.  
 
3. Simulation study 
Geaghan (2002) described an example of a clinical trial designed to study the 
impairment that rheumatoid arthritis produces in the mobility of sufferers. Their original 
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data came from Littell (1996). The trial tested the efficacy of a new drug compared to a 
standard treatment and a placebo. The treatments were administered over 14 weeks to 
57 patients (20 placebo/control (c), 16 standard treatment (s) and 21 new treatment (n)). 
The trial used repeated measurements performed every two weeks. The end point 
variable was a mobility scale, with a continuous range from 0 to 100 %. The results are 
shown in Figure 1. 
The authors of the study used a linear mixed model to fit the mobility results and 
discussed its validity by means of comparing the information produced by the model to 
the real clinical data. 
When fitting such a model, multiple options are available for estimating 
parameters. The relevance of these options in clinical trial modelling is discussed in 
Monleón (2005). To cope with possible residual dependencies, one possibility is to use 
an unstructured covariance matrix, as suggested by Geaghan (2002). This is the option 
that requires the most parameters to be estimated. Assuming that covariance matrices 
are diagonal would make it necessary to estimate fewer parameters (Jenrich et al, 1986). 
The impact of incorrect assumptions on the structure of covariance and residual 
distribution of non-linear mixed models for repeated measurements was studied by El-
Halimi et al (2004) . 
The first-order linear mixed model fitted by Geaghan (2006) to establish the 
relationship between patient mobility and time, with treatment as an additional factor 
was: 
             Yij = (β0+ui0) + (β1+ui1)Timeij + eij               (3)                              
where j = 1, …, m is the index of the measurements through time, i = 1,…, n 
corresponds to patients or cases, β = (β0, β1)’ are the fixed effects and ui = (ui0, ui1)’ are 
the random effects. 
Patient mobility is explained by a set of fixed effects (parameter average values) 
plus random effects associated with deviations of each from the mean value. In the first 
approximation, the dimension of u is 2, that is, there are as many random effects as 
parameters in the model (3), and the number of times u is performed equals the number 
of patients.  
 
In addition, if the model has q experimental factors (drug treatments, interaction 
between time and treatment, other covariates, etc.) with the possibility of each one 
having a random term, the equation would be :  
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Yij = (β0+ui0) + (β1+ui1)xij1 +....+ (βq+uiq)xijq+ eij                                       (4) 
 
where Yij = clinical response variable,  j = time, i = patient or case, β0…βq are fixed 
effects, ui0… uiq are random effects, eij  = global error, xijz = additional covariates, z=1,…, 
q.  
The general model given by (4) is the basis of what is usually called the 
"conceptual model". Assuming that the model has only three terms (treatment, time, and 
their interaction) and that no random component is found for the treatment and the 
interaction, the final conceptual model will be: 
 
yij = (β0+ui0) + βKxijK + (β2+ui2)tij+ β3tij xijk+ eij         (5) 
                                           
where yij  is the percentage of mobility in case (i), at time t (j), for treatment x(k). It is no 
problem that the response is measured as a percentage since the right hand side of (5) is 
Gaussian. A transformed response, such as the logit transformation, could also be 
considered. 
From the dataset described at the beginning of this section, the model parameters 
were estimated using the algorithm PROC MIXED implemented in the SAS software 
(SAS, 1992; PROC MIXED) giving the following estimates: ui0 follows a N(0, 3.0276 
[2.5291,3.7725]) distribution. Similarly, ui2∼ N(0, 0.1740 [0.1422, 0.2241], β2  = 0.165 
[0.08205;0.2479] represent the fixed effect coefficients of the visit times, and the 
covariance between ui0 and ui2 is -0.08889[-0.2498, 0.07207]. The residual distribution 
is eij∼ N(0, 0.7953 [0.7350,0.8663]). The values of the treatment effect βk (-0.8755 [-
2.7827,1.0317]; -0.9630 [-2.9887,1.0626]; 0) and the interaction effect β3 (-0.1944 [-
0.3110,-0.07788]; -0.06006 [-0.1838;-0.06373]; 0) are the estimates of the differences 
from basal treatment (n). The 95% confidence intervals (from asymptotic normal 
theory) for the estimated parameters are indicated in brackets and italics. These 
confidence intervals should be included to highlight the degree of uncertainty and as the 
basis for analysing the sensitivity of the computational model by changing the 
parameter values to other values within these confidence intervals.  
The simulation of model (5) may be helpful in investigating new scenarios, such 
as variation in the power (1-β) when decreasing the sample size of the unexpected 
response to a treatment, or an increase in variability. Data collected in these scenarios 
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may help optimize future clinical trials related to this type of drug, minimizing the 
probability of very expensive errors. 
Equation (5) can be used as a data-generation mechanism. Transformed into 
SAS code, the simulation was performed the number of replications required to reach a 
“previously set accuracy” (Guasch et al, 2002). In Appendix B we suggest a formula for 
calculating the number of simulation replications necessary for a given precision (model 
acceptability); we consider a 10% precision and 15.8% as a semi-interval confidence 
interval of the response variable. Holford et al (1999) specify that the number of 
replications must be based on the target precision of the study. To analyze every 
simulated replication, the same statistical analyses were used as in the original clinical 
trials, obtaining values for GOF, model parameters, and inferential procedures to check 
the differences between factor effects, which we discuss in the next section.  
 
4.  Application to the verification of the simulation models 
We studied confidence intervals for the fixed part, and the variances and 
covariances for the random part parameters of the conceptual model in order to verify 
the computational model. We also calculated the error and the statistical significances 
(p-values) for the main factors (treatment, time, and time/treatment interaction) in this 
model. Our results show that few model parameters differ in the replications of the 
computational model (or fall outside the confidence interval) compared to the estimated 
conceptual model. As we noted above, this method was extremely demanding in terms 
of the time required.  
We further calculated p-values for the drug treatment factor after 100 simulation 
replications (Table 1, Experiment 1). The simulation results reveal that the p-values for 
drug treatments agree with expected values when the null hypothesis is true. 47% of  
experiments had a drug factor p-value < 0.05 (conceptual model p-value for drug 
treatment < 0.05) and 82% of experiments had a time*drug interaction p-value < 0.05 
(conceptual model p-value for drug treatment < 0.05).  Cases not falling within these 
results can be considered as cases with type II error. 
The confidence interval for the conceptual model includes approximately 95% 
of the parameters estimated in 100 simulation replications (mean p-value for the drug 
factor in computational model: 0.14399 [CI95%: 0.1048-0.1831]; Table 1, Experiment 
1). As this is the main factor considered in the clinical trial, it is an argument supporting 
verification of the computational model (Rodríguez-Barrios et al, 2008; Monleón and 
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Ocaña, 2006). Indeed, if the normality conditions are not fulfilled, as in this example 
(previous analysis using distributional test for residuals), these confidence intervals are 
not 95% either. 
To illustrate the use of the proposed measure of stability, PVLi, for the 
verification of simulation models, we performed 10 different simulation experiments 
using 100 replications each time (see appendix B for the methodological details) to 
establish the variation ranges of PVLi using different perturbation conditions. We 
compared the results with p-values for drug and drug*time effects in the cases of 
supposing either compliance or non-compliance with the verification conditions. Table 
1 summarizes our results showing the number of experimental observations, different 
conditions of variation versus the original simulation model, mean PVL, PVL standard 
deviation (Std), PVL range (ul-ll), % p-value<0.05  (mean p-value and 95%CI) for drug 
and time*drug effect and, in the last column, an observational evaluation (author 
criteria) of whether the simulation model is considered verified. ulPVL < 20% was 
established as the maximum distance between the computational and conceptual models 
for verification.  
After different simulation experiments, we observed that the values of PVLi 
using LLK, AIC, AICC and BIC are very similar (Table 1, Experiment 1) so for brevity 
only the LLK results are included in Table 1, experiments 2 to 10. 
The first Experiment in Table 1 is related to the verified computational model 
discussed previously (5) and experiments 2 to 8 are related to the variation in the global 
simulation error (σ). PVLi range (ul-ll) increases a lot when the global error differs 
appreciably from its original value, as in Experiments 2 (σ= 15, PVL range: 143.950-
153.099%) and 3 (σ= 0.1, PVL range: 82.4745-94.4352%). Consequently, non-verified 
simulation models are under consideration in these cases. This observation is supported 
by the results of %p-value<0.05 in Experiment 2 (%p-value drug<0.05 = 15% and p-
value drug*time<0.05= 7%). Figure 4 represents the simulation model under the 
conditions of Experiment 2. The model response does not seem to be the same as in 
Figure 2 for the conceptual model. 
Experiments 4, 5, 6 and 7 are related to the influence of increasing global errors 
(σ) in order to establish when PVLul reaches the 20% limit. In Experiment 4, simulations 
are performed using σ = 0.8663, the upper limit of the estimated global error. The result 
shows that PVLul < 10% in this case.  However, when σ = 1.1 (Experiment 7) PVL range 
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= 10.4815-20.3600%, and when σ > 1.1 (Experiments 5 and 6; σ= 2 and σ= 1.5) PVLul > 
20%. From this it is clear that PVLul reaches the observed 20% limit near the value of 
σ=1.  
The same type of experiments are possible to study the variations in a model 
when fixing the random parameters (β and ui in the previous example) or other scenarios 
like extrapolating the model in time, studied in Experiments 8, 9 and 10. In Experiments 
9 and 10, the same conditions as in the original simulation model were used but the 
duration of the trial was changed to 24 months and the schedule of visits to every 4 
months. In Experiment 9, LLK was normalized with the number of total observations 
(na=349) referred to the original computational model size (nb=399) due to the increase 
or decrease in likelihood. In Experiment 8 PVL range = (2.88799 - 14.12544)% and 
(3.40816 - 16.67919)% in every case all the computational models show the same 
behaviour as the conceptual model. Finally, the experiment was extrapolated to 48 
months and the PVL range was (12.4083 - 24.8824)% reflecting the instability of the 
model, confirmed by the 85% drug p-value < 0.05 in the experiment. This indicates the 
tendency of the model to produce significant differences between drugs in 48-month 
models. So, by means of the PVL range and p-value we can obtain the time period for 
the verified model. 
The PVL range of 0-20% is a good measure of model verification as also observed in 
further simulation experiments using mixed models. These simulation experiments and 
their verification within the framework of clinical trials are presented in previous studies 
(Monleón, 2005), using other data sets and different models, such as linear and non-
linear mixed models. In all cases similar results were observed during the verification 
experiments. These results (Table 2) show a PVL ranges of 4-18%, 0.5-18% and 0.78-
12% for three different clinical trial experiments and confirm that the range of 0 to 20 % 
is correct for the computational model verifying the simulation model. The value of 
PVLIR range (5)  between 0 and 5 % obtained, suggests also that the computational 
model verifies the conceptual model, though this index has not been calculated for all 
the experiments. 
 
5. Discussion 
The main reason to perform simulations is to investigate new scenarios:  varying 
some parameters and then looking how consistent the obtained results are or design new 
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studies where we need to know  how much the results and the precision of the results 
vary under different designs. In this way it can be studied how robust the results are.  
Unfortunately the amount of process to be performed in a simulation are huge 
(conceptual model, computational model, simulation replications, etc) and derives a 
complexity analysis of the results, especially if there is more than one parameter of 
interest and the detection of errors, especially during the model verification. 
Our results coming from several simulation experiments of a clinical trial show 
that the PVL statistic range can be a good measure of stability to establish when a 
computational model verifies the underlying conceptual model. 
Our results show that the PVL statistic range can be a good measure of stability 
for establishing when the computational model is verified, ensuring that the simulation 
computer software, programming and implementation of the conceptual model are 
correct. They suggest that a PVL range of 0-20% indicates that the computational model 
is verified, as an acceptable guideline. One could apply the PVL approach to every 
conceptual model that was tried during the model building process. However the 
simulation of the complex models are still much limited and can be cautious in the 
generalization on this methodology to any statistical model and simulation. 
We can also verify the average simulation predictions using replications. The 
idea could be improved  by calculating simultaneous confidence intervals for all the 
parameters or for all the paths, and not parameter to parameter and period to period as is 
frequently the case. This problem is not present in the PVL range stability measure, 
since only one value is associated with all the simulation replications and  consequently 
improves its. This measure, presented for verification, is useful only when the 
conceptual model remains totally specified by a mathematical expression (as, for 
example, in a mixed model) which allows us to define likelihood confidence intervals. 
On some occasions (frequently coinciding with the most interesting cases to simulate) 
the conceptual model and its implementation in the shape of the conceptual model 
includes aspects not contemplated in these expressions (such as patient withdrawal, time 
between visits, fortuitous facts, queuing model, etc.). This implies that no direct 
confidence intervals or other statistical properties are available. In these cases, 
alternative approaches should be used, such as the graphical analysis summarized in 
Sargent (2003), as well as the opinion of the experts in the specific subject area.  
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 Appendix A. 
 
Mixed models theory 
 
The general form of a mixed model is, 
Y = Xβ + Zu + e,      (A1) 
where Y is an nx1 vector of observed random variables (data). X and Z are known design 
matrices, β is a px1 vector of fixed effects, u is an mx1 vector of random variables 
(random factors) and e is an nx1 vector of random error terms. Vectors u and e are 
distributed randomly with multivariate Gaussian distribution with μ = 0 and covariance 
matrices G (m×m) and R (n×n) respectively. It is supposed that  Cov(u,e)=0, so V(Y)= 
ZGZ’+ R = V. 
If G and R are known, V is also known, and solutions obtained using a 
generalized least squares method to estimate vector β represent the Best Linear 
Unbiased Estimator (BLUE) value of the fixed parameters of the model and the solution 
1u = GZ´V (y´Xβ)−
  is the value of the Best Linear Unbiased Predictor (BLUP) of the 
random effects (Searle et al. [22]). In reality V is unknown, so components of variance 
in G and R are initially estimated to obtain V

 which replaces V in the estimate of β and 
the prediction of u. In the parametric supposition, variance components and covariance 
can be estimated using procedures based on the log likelihood function (Hayman 1960; 
Harville, 1977).  
In the mixed model, the likelihood is calculated from a normal distribution and 
its formula is (Hartley and Rao, 1967): 
( ) exp ( ) ' ( )
n
L V y X V y Xπ β β
−− −⎡ ⎤= − − −⎢ ⎥⎣ ⎦
1
2 12 12
2
     (A2) 
where ( , )N X VY β∼ with 2'V ZGZ Iσ= +  
 
Appendix B.  
 
Determining the number of simulation replications  
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For R independent replications of one random variable Y (mobility in this study) 
the i-th observation of the replication r may be denoted as Yri for i = 1, 2, ..., nr and r = 
1,2,...,R. In the example we have R=100. 
Every simulation replication r (for r=1,…,R) produces nr vectors, usually 
mutually independent. The 1 ,..., rr rnY Y correspond to the nr simulated cases in a general 
replication, or n if the case number is constant. Also, every vector Yri has Tri values of 
Yrit (t=1,…, Tri) that form a sequence (frequently auto-correlated) of random variables 
corresponding to the Y values through time. If the number of time moments is 
considered constant, then Tri=T. 
For simplicity, we consider here that Yri directly corresponds to a scalar 
summary of the T values corresponding to the i-th case during simulation replication r. 
The simple average of the simulation replications of Y is defined as, 
 
θ
=
= =∑
1
1ˆ , 1,2,3,...,
rn
r ri
ir
Y r R
n
        (B1) 
The general sample average is: 
θ θ
=
= ∑
1
1ˆ ˆ
R
r
rR
          (B2) 
The simple simulation variance is defined as: 
 
∑
= −
−=
R
r
r
RR 1
2
2
1
)ˆˆ(1)ˆ(ˆ θθθσ         (B3) 
 
The confidence interval based on the Gaussian distribution of the θ parameter 
with a coverage of 100(1-α)% is calculated as: 
 
α αθ θ θ− −− ≤ ≤ +/ 2, 1 / 2, 1ˆ ˆR Rt S t S
R R
       (B4) 
Where the standard deviation is defined as: 
σ θ= ˆˆ( )S R           (B5) 
The confidence semi-interval for θ is defined as: 
α −= / 2, 1 ,Rt Sg
R
          (B6) 
 15
Accepting the error criterion specified according to confidence interval 1-α as: 
 
θ θ ε α− < ≥ −ˆ( ) 1P  and α ε−− ≤/ 2, 1Rt Sg
R
      (B7) 
we can deduce that, 
α
ε
−≥ / 2, 1 2( )Rt SR      (B8) 
Some authors, such as Guasch et al (2002) suggest formulas to calculate the 
number of simulation replications according to a necessary precision (model 
acceptability) of the response variable, and propose analysing previous replications 
(pilot simulation). In the continuous response variables the number of replications can 
be calculated as: 
 
ε
⎡ ⎤= ⎢ ⎥⎣ ⎦
2( / 2)gR k         (B9) 
 
where k is the number of pilot replications, g is the semi-interval of confidence for the 
response variable expressed as a percentage of the response variable and ε is the 
required precision (1%, 5%, 10%, etc). In experiment we present, if we need to know 
how many replications are necessary for a precision of 15.8% and over 10 pilot 
simulations we observe that the semi-interval of confidence is 10% of the response 
variable (mobility), the number of final replications can be calculated as: 
⎡ ⎤= ⎢ ⎥⎣ ⎦
2(0.158 / 2)10
0.1
R =100 replications (approx.) 
This way of calculating the number of replications is complicated. In many 
scenarios it is very difficult to calculate the confidence semi-interval; it depends on the 
model and the calculations performed. It is also evident that the number of replications 
increases if the confidence interval decreases. 
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Table 1 
 
ne 
 
nb 
 
Condition* PVL Mean PVL Stv 
PVL Range (lower limit (ll) 
- upper limit (ul)) 
% p-value drug<0.05 
Mean  
p-value drug 
[95%CI p-value drug] 
% p-value time x d rug<0.05 
Mean  
p-value time x drug 
[95%CI p-value time x drug] 
Verified model 
using author 
criteria 
1 399 
Simulation model 
σ= 0.79 
LLK:2.0334 
AIC: 2.0213 
AICC: 2.0211 
BIC: 2.0991 
 
1.3763 
1.3680 
1.3680 
1.3591 
 
0.0265-6.6730 
0.0205-6.6329 
0.0203-6.6327 
0.0224-6.5902 
47 
0.14399 
[0.1048-0.1831] 
82 
0.0356 
[0.0198-0.0514] 
YES 
2 399 σ= 15 LLK:149.1466 2.05774 
143.950-153.099 
 
15 
nd 
nd 
 
7 
0.3809420 
[0.3235631 - 0.4383209] 
NO 
3 399 σ= 0.1 LLK: 89.57708 2.35537 82.4745-94.4352 
58 
nd 
nd 
 
86 
0.1076265 
[0.0744647 - 0.1407884] 
NO 
4 399 
σ= 0.8663  
(CI upper limit) 
LLK: 3.809628 2.06651 0.0470112- 8.9070551 
47 
0.1824055        
[0.1330486  - 0.2317625] 
82 
nd 
YES 
 27
5 399 σ= 2 LLK: 42.63919 2.12804 35.5333 - 47.7546 
59 
0.1029978        
[0.0742355 -  0.1317601] 
65 
nd 
NO 
6 399 σ= 1.5 LLK: 28.88558 1.82833 24.3049- 32.6432 
55 
0.1080756        
[0.0726793 - 0.1434720] 
68 
nd 
NO 
7 399 σ= 1.1 LLK: 14.67672 2.02814 10.4815-20.3600 
54 
0.1344879        
[0.0954679 -  0.1735080] 
 
83 
0.0383866 
[0.0187369 - 0.0580363] 
 
YES 
8 349 
Simulation model 
σ= 0.79 
Time = 24 
Visits: 4 months 
LLK: 7.45420 1.90049 2.88799 - 14.12544 
62 
0.1088210        
[0.0706885 - 0.1469536] 
84 
0.0269640 
[0.0154371- 0.0384909] 
YES 
9 349 
Simulation model 
σ= 0.79 
Time = 24 
Visits: 4 months 
LLK**: 8.800693 2.24441 3.40816- 16.67919 
62 
0.1088210        
[0.0706885 - 0.1469536] 
84 
0.0269640 
[0.0154371- 0.0384909] 
YES 
10 456 
Simulation model 
σ= 0.79 
Time = 46 
Visits: 6 months 
LLK**: 18.50607 2.45380 12.4083 - 24.8824 
85 
0.0185545        
[0.0118431 - 0.0252659] 
95 
0.0118831 
[0.0064708 -0.0172954] 
NO 
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Table 2 
 
Trials 
Clinical trial 
Phase 
Indication Replications (n) Trial type1 Mixed model type 2 
PVL range (ll-ul) 
for the estimated 
variability model 
1 III ARTHRITIS 100 R L 0.03 to 6.7 % 
2 I ASTHMA 40 R NL 4 - 18% 
3 IV AIDS 30 R L 0.5 - 18% 
4 II Non real 
40 
(4 scenarios) 
P NL 0.78 - 12% 
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Captions for Figures and Tables 
 
Figure 1: Percentage of mobility for each treatment (1: control; 2: standard; 3: new) in the arthritis clinical trial (mean +/- 95% CI) using real 
data. 
 
Figure 2: Predicted percentage of mobility for each treatment (1: control; 2: standard; 3: new) in the arthritis clinical trial (mean +/- 95% CI) 
using the linear mixed model (conceptual model). 
 
Figure 3: Results of the average paths of % mobility during the clinical trial for the 3 treatments under study (c: control (1); s: standard (2); n: 
new (3)). These paths correspond to the conceptual and simulation models. The confidence intervals are also represented (95% CI) for each of 
them. CT: clinical trial data; SIM: simulation data; CM: conceptual mixed model data. 
 
Figure 4: Percentage of PVL between 100 simulation replications and the conceptual model using the computational model (σ = 0.7953)  ( ulPVL : 
6.65 for LLK, 6.61 for AIC, 6.61 for AICC, 6.57 for BIC). 
 
Figure 5: Results of the average paths of % mobility during the clinical trial for the 3 treatments under study (1: control; 2: standard; 3: new). 
These paths correspond to the simulation model when σ(model)= 15. The confidence intervals are also represented (95% CI) for each of them.  
 
Figure 6: Results of the average paths of % mobility during the clinical trial for the 3 treatments under study (1: control; 2: standard; 3: new). 
These paths correspond to the simulation model. The confidence intervals are also represented (95% CI) for each of them. CT: clinical trial data; 
 30
SIM: simulation data; CM: conceptual mixed model data. Extrapolation of the original conceptual model with the same number of visits and time 
= 24 months, every 4 months. 
 
Figure 7: Results of the average paths of % mobility during the clinical trial for the 3 treatments under study (1: control; 2: standard; 2: new). 
These paths correspond to the simulation model. The confidence intervals are also represented (95% CI) for each of them. CT: clinical trial data; 
SIM: simulation data; CM: conceptual mixed model data. Extrapolation of the conceptual model with the same number of visits and time = 48 
months, every 6 months. 
 
Table 1: Results of the different simulations with the mobility clinical trial, using different conditions (* Variation with respect to conceptual 
mode, ** The number of observations in the conceptual model and in the computational model were different ) ne: Number of experiment; nb: 
num. observations per experiment (case x time); nd: not determined 
(1) P: prospective trial; R: retrospective trial 
(2) L: Linear mixed model; NL Non-linear mixed model 
 
Table 2: Summary of the range of variation obtained in the test of verification based on comparing the range of PVL values between simulation 
replications and the conceptual model in the experiments in Monleón (2005) 
 
 
 
 
